• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersBrainstorm Health

Amazon’s Alexa can now give you detailed information on your medications

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
March 3, 2020, 12:02 PM ET

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.

Good morning, readers.

Some busy times here with the cascade of news surrounding the coronavirus (stay tuned for a big dispatch on that soon—and follow all of Fortune‘s coverage of this public health threat here).

But I did want to share an interesting digital health development. Amazon, which has been steadily expanding its medical ambitions via its moves into the online pharmacy space and, notably, HIPAA compliance for its voice-activated Alexa service, has struck a new medical information partnership with First Databank.

With this alliance, Alexa will be able to answer questions about drug safety, side effects, and drug-on-drug interactions.

“We are proud to bring this essential component of our drug databases directly to consumers through Amazon’s now-ubiquitous and helpful voice-activated technology,” said Bob Katter, president of First Databank, in a statement.

Read on for the day’s news.

Sy Mukherjee
sayak.mukherjee@fortune.com
@the_sy_guy

DIGITAL HEALTH

VistaScan gets FDA clearance for smartphone ultrasounds. The Food and Drug Administration (FDA) has granted clearance to Emagine Solutions Technology's smartphone ultrasound application, dubbed the VistaScan mobile ultrasound system. To be clear, it's not like physicians can just wave their smartphones over a patient—there are probes that must be linked to the tech. But it does allow them to see ultrasound images in real time on ultrasounds and tablets, which can prove critical during an emergency situation. (Medgadget)

INDICATIONS

Novartis' Sandoz unit to pay $195 million fine in landmark antitrust case. Sandoz, the generic drug arm of Swiss pharma giant Novartis, will pay a nearly $200 million fine over a price fixing scandal that's been brewing for more than six years. Sandoz will have to admit guilt as part of the settlement, and the Justice Department says the fine is the largest of its kind for a domestic antitrust suit. (The Associated Press)

THE BIG PICTURE

Supreme Court to take up high stakes Obamacare case (again). To use an outdated reference, Obamacare is a flat circle. Yes, the Affordable Care Act, signed into law ten years ago, is heading to the Supreme Court yet again. The Trump administration has been supporting a lawsuit to scrap the entirety of the law after the repeal of its individual insurance mandate. What the justices will focus on in this latest challenge to the ACA is whether or not that clause is "severable" from the rest of the health law, including its protections for Americans with pre-existing conditions and expansion of Medicaid.

REQUIRED READING

Jack Welch: For a time, the most valuable CEO on earth, by Geoff Colvin

The stock market's gyrations feel historic. But are they?, by Ben Carlson

Everything you wanted to know about Super Tuesday but were afraid to ask, by Nicole Goodkind

Sign up for other Fortune newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Newsletters

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Newsletters

NewslettersMPW Daily
These are the women exec moves you need to know across sports, finance, and media
By Emma HinchliffeMarch 20, 2026
15 hours ago
Elon Musk stares
NewslettersTerm Sheet
SpaceX, OpenAI and Anthropic could be 3 of the biggest venture-backed IPOs of all time
By Allie GarfinkleMarch 20, 2026
19 hours ago
The US Securities and Exchange Commission headquarters in Washington, D.C.
NewslettersCFO Daily
The SEC may be about to blow up the quarterly earnings cycle. Here’s why CFOs are nervous.
By Sheryl EstradaMarch 20, 2026
19 hours ago
NewslettersFortune Tech
After pulling the plug on its own robotaxis, Uber wants back in the game in a big way
By Alexei OreskovicMarch 20, 2026
20 hours ago
NewslettersCEO Daily
Inside the Fortune CEO Initiative dinner: Debt worries, diplomacy, and a chance to have a ‘good debate’
By Diane BradyMarch 20, 2026
21 hours ago
Basecamp Research cofounders Oliver Vince and Glen Gowers photographed walking down a street wearing puffer jackets.
AIEye on AI
Could data from 100 million species help cure disease? One startup is betting on it
By Sharon GoldmanMarch 19, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.